APA (7th ed.) Citation

Do, T. X., Nguyen, H. T., Nguyen, P. T. L., Kieu, M. T. T., Duong, T. V., & Pham, V. N. H. (2026). Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country. PLoS ONE, 21(4), 1. https://doi.org/10.1371/journal.pone.0345212

Chicago Style (17th ed.) Citation

Do, Thang Xuan, Ha Thi Nguyen, Phuong Thi Lan Nguyen, Mai Thi Tuyet Kieu, Tuan Viet Duong, and Van Nu Hanh Pham. "Cost-utility Analysis of Lenvatinib and Sorafenib for the First-line Treatment of Unresectable Hepatocellular Carcinoma in Vietnam: Evidence from a Lower-middle Income Country." PLoS ONE 21, no. 4 (2026): 1. https://doi.org/10.1371/journal.pone.0345212.

MLA (9th ed.) Citation

Do, Thang Xuan, et al. "Cost-utility Analysis of Lenvatinib and Sorafenib for the First-line Treatment of Unresectable Hepatocellular Carcinoma in Vietnam: Evidence from a Lower-middle Income Country." PLoS ONE, vol. 21, no. 4, 2026, p. 1, https://doi.org/10.1371/journal.pone.0345212.